Treatment is the only single infusion gene therapy for the treatment of severe haemophilia B
News
2023 PM Society Awards – Winners Announced
21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board
Destiny releases pivotal phase 2 data involving XF-73 nasal gel
Study shows significant reduction of nasal S. aureus in cardiac surgery patients before surgery
Debiopharm reveals phase 1/2 GaLuCi research results
The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate
Ono and Macomics join forces to develop cancer therapy
The partnership will involve progressing macrophage-targeting antibody treatment for cancer
Recommendation from NICE for PTC Therapeutics gene therapy
Eladocagene exuparvovec is for children with ultra-rare genetic disorder in final draft guidance
Evgen reveals results from pivotal phase 1b trial
Study involves SFX-01 candidate and emerging preliminary pharmacokinetic data from study
ABPI responds to rebooted MHRA clinical trials framework
Measures include a requirement to publicly register studies and share results among research participants
Vitestro raises vital funding for autonomous blood drawing device
Company raises €12m in financing with a view to entering to the European market
Astellas and Pfizer reveal positive results for Xtandi
Research data follows phase 3 EMBARK trial and involves men with non-metastatic prostate cancer
AstraZeneca and MSD’s Lynparza gets green light
Combination therapy treat patients with metastatic castration-resistant prostate cancer
Genedrive’s MT-RNR1 test achieves roll out in Greater Manchester
Company will also operate work on particular initiatives across an additional five neonatal sites
Great Ormond Street Hospital and Leucid Bio collaborate
GOSH will collaborate with Leucid at the Zayed Centre for Research into Rare Disease in Children
iOnctura reveals roginolisib research results
Therapy prevents tumour proliferation while breaking immune tolerance among cancer patients
NICE approves funding for Novartis gene therapy
Funding is for onasemnogene abeparvovec and concerns babies with spinal muscular atrophy
